Product Name
Collagenase 3 (MMP13), Recombinant Protein
Full Product Name
Recombinant Human Collagenase 3
Product Synonym Names
Matrix metalloproteinase-13; MMP-13
Product Gene Name
MMP13 recombinant protein
[Similar Products]
Research Use Only
For Research Use Only. Not for use in diagnostic procedures.
Sequence Positions
Full Length, 104-471aa
3D Structure
ModBase 3D Structure for P45452
Purity/Purification
Greater than 90% as determined by SDS-PAGE.
Form/Format
20mM Tris-HCl based buffer, pH8.0
Preparation and Storage
Store at -20 degree C, for extended storage, conserve at -20 degree C or -80 degree C. Repeated freezing and thawing is not recommended. Store working aliquots at 4 degree C for up to one week.
Other Notes
Small volumes of MMP13 recombinant protein vial(s) may occasionally become entrapped in the seal of the product vial during shipment and storage. If necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the container`s cap. Certain products may require to ship with dry ice and additional dry ice fee may apply.
Related Product Information for
MMP13 recombinant protein
Plays a role in the degradation of extracellular matrix proteins including fibrillar collagen, fibronectin, TNC and ACAN. Cleaves triple helical collagens, including type I, type II and type III collagen, but has the highest activity with soluble type II collagen. Can also degrade collagen type IV, type XIV and type X. May also function by activating or degrading key regulatory proteins, such as TGFB1 and CTGF. Plays a role in wound healing, tissue rodeling, cartilage degradation, bone development, bone mineralization and ossification. Required for normal bryonic bone development and ossification. Plays a role in the healing of bone fractures via endochondral ossification. Plays a role in wound healing, probably by a mechanism that involves proteolytic activation of TGFB1 and degradation of CTGF. Plays a role in keratinocyte migration during wound healing. May play a role in cell migration and in tumor cell invasion.
NCBI/Uniprot data below describe general gene information for MMP13. It may not necessarily be applicable to this product.
NCBI Accession #
NP_002418.1
[Other Products]
NCBI GenBank Nucleotide #
NM_002427.3
[Other Products]
UniProt Primary Accession #
P45452
[Other Products]
UniProt Secondary Accession #
Q6NWN6; A8K846; B2RCZ3[Other Products]
UniProt Related Accession #
P45452[Other Products]
NCBI Official Full Name
collagenase 3 preproprotein
NCBI Official Synonym Full Names
matrix metallopeptidase 13
NCBI Official Symbol
MMP13??[Similar Products]
NCBI Official Synonym Symbols
CLG3; MDST; MANDP1; MMP-13
??[Similar Products]
NCBI Protein Information
collagenase 3
UniProt Protein Name
Collagenase 3
UniProt Synonym Protein Names
Matrix metalloproteinase-13; MMP-13
Protein Family
Collagenase
UniProt Gene Name
MMP13??[Similar Products]
UniProt Synonym Gene Names
MMP-13??[Similar Products]
NCBI Summary for MMP13
This gene encodes a member of the peptidase M10 family of matrix metalloproteinases (MMPs). Proteins in this family are involved in the breakdown of extracellular matrix in normal physiological processes, such as embryonic development, reproduction, and tissue remodeling, as well as in disease processes, such as arthritis and metastasis. The encoded preproprotein is proteolytically processed to generate the mature protease. This protease cleaves type II collagen more efficiently than types I and III. It may be involved in articular cartilage turnover and cartilage pathophysiology associated with osteoarthritis. Mutations in this gene are associated with metaphyseal anadysplasia. This gene is part of a cluster of MMP genes on chromosome 11. [provided by RefSeq, Jan 2016]
UniProt Comments for MMP13
MMP13: Degrades collagen type I. Does not act on gelatin or casein. Could have a role in tumoral process. Defects in MMP13 are the cause of spondyloepimetaphyseal dysplasia Missouri type (SEMD-MO). A bone disease characterized by moderate to severe metaphyseal changes, mild epiphyseal involvement, rhizomelic shortening of the lower limbs with bowing of the femora and/or tibiae, coxa vara, genu varum and pear-shaped vertebrae in childhood. Epimetaphyseal changes improve with age. Defects in MMP13 are the cause of metaphyseal anadysplasia type 1 (MANDP1). Metaphyseal anadysplasia consists of an abnormal bone development characterized by severe skeletal changes that, in contrast with the progressive course of most other skeletal dysplasias, resolve spontaneously with age. Clinical characteristics are evident from the first months of life and include slight shortness of stature and a mild varus deformity of the legs. Patients attain a normal stature in adolescence and show improvement or complete resolution of varus deformity of the legs and rhizomelic micromelia. Belongs to the peptidase M10A family.
Protein type: EC 3.4.24.-; Protease; Secreted; Secreted, signal peptide
Chromosomal Location of Human Ortholog: 11q22.2
Cellular Component: extracellular region; extracellular space
Molecular Function: calcium ion binding; collagen binding; metalloendopeptidase activity; serine-type endopeptidase activity; zinc ion binding
Biological Process: collagen catabolic process; extracellular matrix disassembly
Disease: Metaphyseal Dysplasia, Spahr Type; Spondyloepimetaphyseal Dysplasia, Missouri Type
Research Articles on MMP13
1. these findings support roles for both cFOS (indirect) and ATF3 (direct) in effecting MMP13 transcription in human chondrocytes.
Precautions
All of MyBioSource's Products are for scientific laboratory research purposes and are not for diagnostic, therapeutics, prophylactic or in vivo use. Through your purchase, you expressly represent and warrant to MyBioSource that you will properly test and use any Products purchased from MyBioSource in accordance with industry standards. MyBioSource and its authorized distributors reserve the right to refuse to process any order where we reasonably believe that the intended use will fall outside of our acceptable guidelines.
Disclaimer
While every efforts were made to ensure the accuracy of the information provided in this datasheet, MyBioSource will not be liable for any omissions or errors contained herein. MyBioSource reserves the right to make changes to this datasheet at any time without prior notice.
It is the responsibility of the customer to report product performance issues to MyBioSource within 30 days of receipt of the product. Please visit our Terms & Conditions page for more information.